TransMedics Group (TMDX) Stock Forecast & Price Target

Compare

1,759 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TMDX Analyst Ratings

Moderate Buy

8 Buy

3 Hold

0 Sell

Based on 11 analysts giving stock ratings to

TransMedics

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TMDX Stock 12 Month Forecast

Average Price Target

$160.30

▲(29.82% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $160.30 with a high forecast of $190.00 and a low forecast of $130.00. The average price target represents a 29.82% change from the last price of $123.48.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","98":"$98","129":"$129","160":"$160","191":"$191"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$190.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":160.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$160.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$130.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,98,129,160,191],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147,150.30769230769232,153.6153846153846,156.92307692307693,160.23076923076923,163.53846153846155,166.84615384615384,170.15384615384616,173.46153846153845,176.76923076923077,180.07692307692307,183.3846153846154,186.69230769230768,{"y":190,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147,148.02307692307693,149.04615384615386,150.06923076923078,151.09230769230768,152.1153846153846,153.13846153846154,154.16153846153847,155.1846153846154,156.20769230769233,157.23076923076923,158.25384615384615,159.27692307692308,{"y":160.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147,145.69230769230768,144.3846153846154,143.07692307692307,141.76923076923077,140.46153846153845,139.15384615384616,137.84615384615384,136.53846153846155,135.23076923076923,133.92307692307693,132.6153846153846,131.30769230769232,{"y":130,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$190.00

Average Price Target$160.30

Lowest Price Target$130.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Josh Jennings

TD Cowen

$190

Buy

53.87%

Upside

Reiterated

03/13/26

Reiterating Buy on TransMedics: Defensible OCS Leadership and Organ Management Expansion Drive Sustained Growth Outlook

William Plovanic

Canaccord Genuity

$152

Buy

23.10%

Upside

Reiterated

03/09/26

TransMedics: Early 2026 DCD and Liver Transplant Momentum Supports Upside and Maintained Buy Rating

Thomas Stephan

Stifel Nicolaus

$115→$130

Hold

5.28%

Upside

Assigned

03/09/26

TransMedics price target raised to $130 from $115 at StifelTransMedics price target raised to $130 from $115 at Stifel

Matthew O'Brien

Piper Sandler

$147→$160

Buy

29.58%

Upside

Reiterated

03/03/26

Piper Sandler Sticks to Their Buy Rating for TransMedics Group (TMDX)

Suraj Kalia

Oppenheimer

$150→$175

Buy

41.72%

Upside

Reiterated

02/25/26

Oppenheimer Sticks to Their Buy Rating for TransMedics Group (TMDX)

Allen Gong

J.P. Morgan

$114→$149

Hold

20.67%

Upside

Reiterated

02/25/26

TransMedics price target raised to $149 from $114 at JPMorganTransMedics price target raised to $149 from $114 at JPMorgan

David Rescott

Robert W. Baird

$154→$168

Buy

36.05%

Upside

Reiterated

02/25/26

TransMedics price target raised to $168 from $154 at BairdTransMedics price target raised to $168 from $154 at Baird

Daniel Markowitz CFA

Evercore ISI

$155→$170

Buy

37.67%

Upside

Reiterated

02/25/26

TransMedics price target raised to $170 from $155 at Evercore ISITransMedics price target raised to $170 from $155 at Evercore ISI

Michael Matson

Needham

$166→$174

Buy

40.91%

Upside

Reiterated

02/25/26

Analysts' Top Healthcare Picks: Vaxcyte (PCVX), TransMedics Group (TMDX)

Patrick Wood

Morgan Stanley

$135

Hold

9.33%

Upside

Reiterated

02/25/26

Balancing Strong Execution With Long-Term Catalysts: Why TransMedics Merits a Hold Rating

Ryan Daniels

William Blair

―

Buy

―

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Ceribell, Inc. (NASDAQ: CBLL)

Young Li

Jefferies

$145

Buy

17.43%

Upside

Reiterated

10/28/25

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Josh Jennings

TD Cowen

$190

Buy

53.87%

Upside

Reiterated

03/13/26

Reiterating Buy on TransMedics: Defensible OCS Leadership and Organ Management Expansion Drive Sustained Growth Outlook

William Plovanic

Canaccord Genuity

$152

Buy

23.10%

Upside

Reiterated

03/09/26

TransMedics: Early 2026 DCD and Liver Transplant Momentum Supports Upside and Maintained Buy Rating

Thomas Stephan

Stifel Nicolaus

$115→$130

Hold

5.28%

Upside

Assigned

03/09/26

TransMedics price target raised to $130 from $115 at StifelTransMedics price target raised to $130 from $115 at Stifel

Matthew O'Brien

Piper Sandler

$147→$160

Buy

29.58%

Upside

Reiterated

03/03/26

Piper Sandler Sticks to Their Buy Rating for TransMedics Group (TMDX)

Suraj Kalia

Oppenheimer

$150→$175

Buy

41.72%

Upside

Reiterated

02/25/26

Oppenheimer Sticks to Their Buy Rating for TransMedics Group (TMDX)

Allen Gong

J.P. Morgan

$114→$149

Hold

20.67%

Upside

Reiterated

02/25/26

TransMedics price target raised to $149 from $114 at JPMorganTransMedics price target raised to $149 from $114 at JPMorgan

David Rescott

Robert W. Baird

$154→$168

Buy

36.05%

Upside

Reiterated

02/25/26

TransMedics price target raised to $168 from $154 at BairdTransMedics price target raised to $168 from $154 at Baird

Daniel Markowitz CFA

Evercore ISI

$155→$170

Buy

37.67%

Upside

Reiterated

02/25/26

TransMedics price target raised to $170 from $155 at Evercore ISITransMedics price target raised to $170 from $155 at Evercore ISI

Michael Matson

Needham

$166→$174

Buy

40.91%

Upside

Reiterated

02/25/26

Analysts' Top Healthcare Picks: Vaxcyte (PCVX), TransMedics Group (TMDX)

Patrick Wood

Morgan Stanley

$135

Hold

9.33%

Upside

Reiterated

02/25/26

Balancing Strong Execution With Long-Term Catalysts: Why TransMedics Merits a Hold Rating

Ryan Daniels

William Blair

―

Buy

―

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Ceribell, Inc. (NASDAQ: CBLL)

Young Li

Jefferies

$145

Buy

17.43%

Upside

Reiterated

10/28/25

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TransMedics Group

3 Months

xxx

Success Rate

19/32 ratings generated profit

Average Return

+18.63%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 59.38% of your transactions generating a profit, with an average return of +18.63% per trade.

1 Year

William PlovanicCanaccord Genuity

Success Rate

24/36 ratings generated profit

Average Return

+45.31%

reiterated a buy rating 9 days ago

Copying William Plovanic's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +45.31% per trade.

2 Years

xxx

Success Rate

28/35 ratings generated profit

Average Return

+77.85%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +77.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMDX Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TMDX has received 63 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. TMDX average Analyst price target in the past 3 months is 160.30.

Each month's total comprises the sum of three months' worth of ratings.

TMDX Financial Forecast

TMDX Earnings Forecast

Next quarter’s earnings estimate for TMDX is $0.63 with a range of $0.45 to $0.82. The previous quarter’s EPS was $2.62. TMDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.

TMDX Sales Forecast

Next quarter’s sales forecast for TMDX is $174.25M with a range of $167.10M to $184.80M. The previous quarter’s sales results were $160.76M. TMDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.

TMDX Stock Forecast FAQ

What is TMDX’s average 12-month price target, according to analysts?

Based on analyst ratings, TransMedics Group Inc’s 12-month average price target is 160.30.

What is TMDX’s upside potential, based on the analysts’ average price target?

TransMedics Group Inc has 29.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TMDX a Buy, Sell or Hold?

TransMedics Group Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 0 sell ratings.

What is TransMedics Group Inc’s price target?

The average price target for TransMedics Group Inc is 160.30. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $190.00 ,the lowest forecast is $130.00. The average price target represents 29.82% Increase from the current price of $123.48.

What do analysts say about TransMedics Group Inc?

TransMedics Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TMDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

TransMedics Group (TMDX) Stock Forecast & Price Target

TMDX Analyst Ratings

TMDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TransMedics Group

TMDX Analyst Recommendation Trends

TMDX Financial Forecast

TMDX Earnings Forecast

TMDX Sales Forecast

TMDX Stock Forecast FAQ

Detailed List of Analyst Forecasts